Predictive factors for pericardial effusion identified by heart dose-volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy

British Journal of Radiology

Volumn 88, Issue 1046, 2015, Pages

  Hayashi, K ^a   Fujiwara, Y ^b   Nomura, M ^a   Kamata, M ^a   Kojima, H ^a   Kohzai, M ^a   Sumita, K ^a   Tanigawa, N ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; NEDAPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CATHETER ABLATION; CHEMORADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DOSE VOLUME HISTOGRAM; DRUG MEGADOSE; ESOPHAGUS CANCER; FEMALE; GASTROINTESTINAL TOXICITY; HEART FAILURE; HEART VOLUME; HISTOGRAM; HUMAN; INDUCTION CHEMOTHERAPY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PERICARDIAL EFFUSION; PLEURODESIS; PREDICTOR VARIABLE; RADIATION DOSE; RADIATION FIELD; RADIATION INJURY; RETROSPECTIVE STUDY; TUMOR VOLUME; COMPLICATION; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; ESOPHAGEAL NEOPLASMS; FOLLOW UP; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; THREE DIMENSIONAL IMAGING; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMAGING, THREE-DIMENSIONAL; MALE; MIDDLE AGED; PERICARDIAL EFFUSION; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84921646413     PISSN: 00071285     EISSN: 1748880X     Source Type: Journal    
DOI: 10.1259/bjr.20140168     Document Type: Article

References (21)

1. The Editorial Board of the Cancer Statistics in Japan. Cancer Statistics in Japan 2010. Tokyo, Japan: Foundation for Promotion of Cancer Research; 2010.
2. Hiroto I, Haruji U, Soji O, Hiroshi T, Takao S, Masayuki S, et al; Japan Esophageal Society. The registration committee for esophageal cancer. Comprehensive registry of esophageal cancer in Japan. 3rd edn. 20 June 2002. Available from: http://esophagus.jp/crec.html
3. Ajani JA, Bentrem DJ, Besh S, et al. National Comprehensive Cancer Network cinical practice guidelines in oncology: esophageal and esophagogastric junction cancers. Version 1, 2013. Available from: www.NCCN.org
4. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 1999;281:1623-7.
5. Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, et al; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (JCOG). Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys 2011;81:684-90. doi:10.1016/j.ijrobp. 2010.06.033
6. Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol 2004;34:615-19.
7. Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593-8.
8. Hironaka S, Ohtsu A, Boku N, Muto M, Nagashima F, Saito H, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T (2-3) N (any) M0 squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 2003;57:425-33.
9. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III trial of combinedmodality therapy for esophageal cancer: highdose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167-74.
10. Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003;21:2697-702.
11. Wei X, Liu HH, Tucker SL, Wang S, Mohan R, Cox JD, et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys 2008;70:707-14. doi:10.1016/j. ijrobp. 2007.10.056
12. Drzymala RE, Mohan R, Brewstar L, Chu J, Goitein M, Harms W, et al. Dose-volume histograms. Int J Radiat Oncol Biol Phys 1991;21:71-8.
13. Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th edn. New York, NY: Springer; 2009.
14. Kodaira T, Fuwa N, Kamata M, Furutani K, Tachibana H, Yamazaki T. Single-institute phase I/II trial of alternating chemoradiotherapy with 5-FU and nedaplatin for esophageal carcinoma. Anticancer Res 2006;26:471-8.
15. Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamura T, et al. Phase I study and pharmacological analysis of cis-diammine (glycolato) platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion. Cancer Res 1991;51:1472-7.
16. Sai H, Mitsumori M, Yamauchi C, Araki N, Okumura S, Nagata Y, et al. Concurrent chemoradiotherapy for esophageal cancer: comparison between intermittent standarddose cisplatin with 5-fluorouracil and daily low-dose cisplatin with continuous infusion of 5-fluorouracil. Int J Clin Oncol 2004;9:149-53.
17. Fukada J, Shigematsu N, Ohashi T, Shiraishi Y, Takeuchi H, Kawaguchi O, et al. Pericardial and pleural effusions after definitive radiotherapy for esophageal cancer. J Radiat Res 2012;53:447-53.
18. Kumekawa Y, Kaneko K, Ito H, Kurahashi T, Konishi K, Katagiri A, et al. Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Gastroenterol 2006;41:425-32.
19. Morota M, Gomi K, Kozuka T, Chin K, Matsuura M, Oguchi M, et al. Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys 2009;75:122-8. doi:10.1016/j.ijrobp. 2008.10.075
20. Aleman BM, Van Den Belt-Dusebout AW, De Bruin ML, Van't Veer MB, Baaijens MH, De Boer JP, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878-86.
21. Prosnitz RG, Hubbs JL, Evans ES, Zhou SM, Yu X, Blazing MA, et al. Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment. Cancer 2007;110:1840-50.